ABLIVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1648 SEK | +1.10% |
|
+3.26% | -32.87% |
| Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
Presentation Operator MessageOperator (Operator)Hello, and welcome to Abliva Audiocast Telecon...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
Calendar
2024-05-20
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.87% | 20.28M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ABLI Stock
- News Abliva AB
- Transcript : Abliva AB - Special Call
